Skip to main content
SpringerLink
Log in

Therapie mit positiv inotropen Substanzen

  • Conference paper
Medikamentöse Behandlung des Postinfarktpatienten nach CAST

  • 43 Accesses

Zusammenfassung

Indikation für eine Therapie mit positiv inotropen Substanzen ist die Myokardinsuffizienz, zu deren häufigsten Ursachen die koronare Herzkrankheit und der Herzinfarkt gehören. Positiv inotrope Substanzen sind dadurch definiert, daß sie die myokardiale Kontraktionskraft unabhängig von ihren physiologischen Determinanten Frequenz und Vordehnung steigern. Die positiv inotrope Wirkung betrifft grundsätzlich nur kontraktile und zu einer Kontraktionskraftsteigerung noch fähige Myokardbezirke. Positiv inotrope Substanzen greifen somit nicht kausal an den der Myokardinsuffizienz zugrundeliegenden pathobiochemischen, pathophysiologischen oder pathomorphologischen Veränderungen an. Sie können jedoch Symptome der Myokardinsuffizienz bessern, indem sie das zu geringe Schlagvolumen wieder vergrößern. Ungeklärt ist die Frage, wie die Prognose der Herzinsuffizienz durch eine Langzeittherapie mit positiv inotropen Substanzen beeinflußt wird.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Beiser GD, Epstein SE, Goldstein RE, Stampfer M, Braunwald E (1970) Comparison of the peak inotropic effects of a catecholamine and a digitalis glycoside in the intact canine heart. Circulation 42: 805–813

    PubMed  CAS  Google Scholar 

  2. Brückner R, Meyer W, Mügge A, Schmitz W, Scholz H (1984) alphaadrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol 99: 345–347

    Article  PubMed  Google Scholar 

  3. Cohn JN, Tristani FE, Khatri IM (1969) Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. Am Heart J 78: 318–330

    Article  PubMed  CAS  Google Scholar 

  4. Colucci WS, Denniss AR, Quigg R, Leatherman GF, Rocco MB, Gauthier (1987) Lack of positive inotropic effect of alpha-adrenergic receptor stimulation by dobutamine in patients with congestive heart failure. Circulation 76 (Suppl II: IV–71

    Google Scholar 

  5. Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments (two parts). New Engl J Med 314: 290–299; 349–358

    Article  PubMed  CAS  Google Scholar 

  6. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New Engl J Med 320: 677–683

    Article  PubMed  CAS  Google Scholar 

  7. Dosemeci A, Dhallan RS, Cohen NM, Lederer WJ, Rogers TB (1988) Phorbol ester increases calcium current and simulates the effects of angiotensin II on cultured neonatal rat heart myocytes. Circ Res 62: 347–357

    PubMed  CAS  Google Scholar 

  8. Evans DB, Weishaar RE, Kaplan HR (1982) Strategy for the discovery and development of a positive inotropic agent. Pharmac Ther 61: 303–330

    Article  Google Scholar 

  9. Feldman AM, Bristow MR (1990) The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology 77 (Suppl 1): 1–32

    Article  PubMed  Google Scholar 

  10. Goldberg LI, Rajfer SI (1985) Dopamine receptors: applications in clinical cardiology. Circulation 72: 245–248

    Article  PubMed  CAS  Google Scholar 

  11. Honerjäger P (1982) Cardioactive substances that prolong the open state of sodium channels. Rev Physiol Biochem Pharmacol 92: 1–74

    Article  PubMed  Google Scholar 

  12. Honerjäger P (1986) Die inotrope Digitaliswirkung auf molekularer und zellulärer Ebene. Dt Ärzteblatt 83: 535–539

    Google Scholar 

  13. Honerjäger P (1988) Drugs affecting cardiac calcium metabolism. In: Baker PF (ed) Handbook of experimental pharmacology, vol. 83. Springer, Heidelberg New York, pp 383–410

    Google Scholar 

  14. Honerjäger P (1989) Pharmacology of positive inotropic phosphodiesterase III inhibitors. Eur Heart J 10 (Suppl C): 25–31

    PubMed  Google Scholar 

  15. Honerjäger P, Heiss A, Schäfer-Körting M, Schönsteiner G, Reiter M (1984) UD-CG 115 — a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guineapig papillary muscle. Naunyn-Schmiedeberg’s Arch Pharmacol 325: 259–269

    Article  PubMed  Google Scholar 

  16. Honerjäger P, Klockow M, Schönsteiner G, Jonas R (1989) Imidazopyridines: roles of pyridine nitrogen position and methylsulfinyl oxygen for in vitro positive inotropic mechanism and chronotropic activity. J Cardiovasc Pharmacol 13: 673–681

    PubMed  Google Scholar 

  17. Kass RS, Lederer WJ, Tsien RW, Weingart R (1978) Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibres. J Physiol (Lond) 281: 187–208

    CAS  Google Scholar 

  18. Lee JA, Allen DG (1990) Calcium sensitisers. Brit Med J 300: 551–552

    Article  PubMed  CAS  Google Scholar 

  19. Lee JA, Rüegg JC, Allen DG (1989) Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ventricular muscle. Clin Sei 76: 609–618

    CAS  Google Scholar 

  20. Nathan D, Beeler GW (1975) Electrophysiologic correlates of the inotropic effects of isoproterenol in canine myocardium. J mol cell Cardiol 7: 1–15

    Article  PubMed  CAS  Google Scholar 

  21. Porzig H (1989) Voltage-gated cardiac Ca channels as a target for new positive inotropic drugs. J Cardiovasc Pharmacol 14: S15–S19

    Article  PubMed  CAS  Google Scholar 

  22. Reiter M (1981) The positive inotropic action of cardioactive steroids on cardiac ventricular muscle. In: Greeff K (ed) Handbook of experimental pharmacology, vol 56/1. Springer, Heidelberg New York, pp 187–219

    Google Scholar 

  23. Scholtysik G, Quast U (1986) Pharmakologie des Natriumkanals in Herzzellen von Säugetieren: Bereicherung durch DPI 201-106. Triangel 25: 105–116

    Google Scholar 

  24. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336: 1–6

    Article  Google Scholar 

  25. Tuttle RR, Mills J (1975) Dobutamine. Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36: 185–196

    PubMed  CAS  Google Scholar 

  26. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82: 774–780

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie, Technischen Universität München, Biedersteiner Straße 29, 8000, München 40, Germany

    Prof. Dr. med. P. Honerjäger

Authors
  1. Prof. Dr. med. P. Honerjäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I. Medizinische Klinik, Technischen Universität München Klinikum rechts der Isar, Ismaninger Straße 22, 8000, München 80, Germany

    Georg Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Dr. Dietrich Steinkopff Verlag, GmbH Co. KG, Darmstadt

About this paper

Cite this paper

Honerjäger, P. (1991). Therapie mit positiv inotropen Substanzen. In: Schmidt, G. (eds) Medikamentöse Behandlung des Postinfarktpatienten nach CAST. Steinkopff. https://doi.org/10.1007/978-3-642-85414-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85414-9_13

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-85415-6

  • Online ISBN: 978-3-642-85414-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation